In an RCT of 960 adults with P vivax malaria and normal G6PD, unsupervised 7-day high-dose primaquine did not significantly reduce 6-month recurrence vs 14-day low-dose (13.0% vs 18.5%; HR 0.66, p=0.063). Secondary: single-dose tafenoquine 12.6% (HR 0.64).
RCTn = 960
Degaga et al. Effectiveness and safety of 7-day high-dose primaquine and single-dose tafenoquine versus 14-day low-dose primaquine in patients with Plasmodium vivax malaria (EFFORT): a multicentre, open-label, randomised, controlled, superiority trial